What 9 Analyst Ratings Have To Say About DICE Therapeutics
Portfolio Pulse from Benzinga Insights
Nine analysts have provided ratings for DICE Therapeutics (NASDAQ:DICE) in the last quarter, with two being bullish and seven indifferent. The average price target is $50.78, which is higher than the current price of $47.55. This average represents a 14.66% decrease from the previous average price target of $59.50.
August 09, 2023 | 8:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts' average price target for DICE Therapeutics is $50.78, indicating potential upside from the current price of $47.55. However, this target is a 14.66% decrease from the previous target.
The average price target set by analysts suggests a potential upside for DICE Therapeutics, which could positively impact the stock price. However, the decrease in the average price target compared to the previous one might indicate less optimism about the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100